(RMD) ResMed - NYSE
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 27.362m USD | Total Return: -24.1% in 12m
Avg Turnover: 291M
EPS Trend: 99.4%
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
Confidence
ResMed Inc. (NYSE: RMD) develops, manufactures, and markets medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders, operating through two segments: Sleep and Breathing Health, and Residential Care Software. The company is classified within the Health Care Equipment sub-industry and combines a hardware-plus-software business model, selling physical devices alongside recurring SaaS offerings.
In its core sleep apnea franchise, ResMed supplies diagnostic tools (e.g., ApneaLink Air, NightOwl) used in clinics, hospitals, and home settings, along with connected therapy management platforms such as AirView for clinicians and myAir for patients. These connected solutions enable remote monitoring, device setting adjustments, and patient engagement tools that support therapy compliance.
Through its Residential Care Software segment, the company offers enterprise solutions-including Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN-serving home medical equipment providers, pharmacies, home health and hospice agencies, and skilled nursing facilities with electronic health records, billing, coding, and analytics capabilities.
Founded in 1989 and headquartered in San Diego, California, ResMed sells both domestically and internationally, with growth supported by increased diagnosis rates of sleep-disordered breathing and broader demand for digital health tools in post-acute and home-based care settings.
- GLP-1 weight loss drugs threaten sleep apnea device demand
- Philips CPAP recall drives ResMed market share gains
- Residential Care Software revenue accelerates via MatrixCare and MEDIFOX DAN acquisitions
| Net Income: 1.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA -0.77 > 1.0 |
| NWC/Revenue: 48.99% < 20% (prev 45.16%; Δ 3.82% < -1%) |
| CFO/TA 0.22 > 3% & CFO 1.89b > Net Income 1.52b |
| Net Debt (-638.3m) to EBITDA (2.19b): -0.29 < 3 |
| Current Ratio: 3.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (147.0m) vs 12m ago -0.12% < -2% |
| Gross Margin: 61.69% > 18% (prev 58.53%; Δ 3.16% > 0.5%) |
| Asset Turnover: 67.74% > 50% (prev 66.36%; Δ 1.37% > 0%) |
| Interest Coverage Ratio: 55.55 > 6 (EBIT TTM 1.93b / Interest Expense TTM 34.8m) |
| A: 0.31 (Total Current Assets 4.06b - Total Current Liabilities 1.35b) / Total Assets 8.78b |
| B: 0.79 (Retained Earnings 6.96b / Total Assets 8.78b) |
| C: 0.24 (EBIT TTM 1.93b / Avg Total Assets 8.18b) |
| D: 2.83 (Book Value of Equity 6.49b / Total Liabilities 2.29b) |
| Altman-Z'' = 9.17 = AAA |
| DSRI: 1.01 (Receivables 1.05b/939.5m, Revenue 5.54b/5.02b) |
| GMI: 0.95 (GM 58.53% / 61.69%) |
| AQI: 0.94 (AQ_t 0.45 / AQ_t-1 0.49) |
| SGI: 1.10 (Revenue 5.54b / 5.02b) |
| TATA: -0.04 (NI 1.52b - CFO 1.89b) / TA 8.78b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of June 24, 2026, the stock is trading at USD 191.26 with a total of 872,769 shares traded. Over the past week, the price has changed by -0.77%, over one month by -8.04%, over three months by -15.85% and over the past year by -24.12%.
Current recommended Stop Loss: 184.70 (which is 3.4% or 1.2 ATR below the current price).
ResMed has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy RMD.
- StrongBuy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 262.2 | 37.1% |
P/E Trailing = 18.1724
P/E Forward = 15.9236
P/S = 4.941
P/B = 4.2148
P/EG = 1.1088
Revenue TTM = 5.54b USD
EBIT TTM = 1.93b USD
EBITDA TTM = 2.19b USD
Long Term Debt = 404.2m USD (from longTermDebt, last quarter)
Short Term Debt = 289.2m USD (from shortTermDebt, last quarter)
Debt = 1.02b USD (from shortLongTermDebtTotal, last quarter) + Leases 179.1m
Net Debt = -638.3m USD (calculated: Debt 1.02b - CCE 1.66b)
Enterprise Value = 26.7b USD (27.4b + Debt 1.02b - CCE 1.66b)
Interest Coverage Ratio = 55.55 (Ebit TTM 1.93b / Interest Expense TTM 34.8m)
EV/FCF = 15.29x (Enterprise Value 26.7b / FCF TTM 1.75b)
FCF Yield = 6.54% (FCF TTM 1.75b / Enterprise Value 26.7b)
FCF Margin = 31.57% (FCF TTM 1.75b / Revenue TTM 5.54b)
Net Margin = 27.44% (Net Income TTM 1.52b / Revenue TTM 5.54b)
Gross Margin = 61.69% ((Revenue TTM 5.54b - Cost of Revenue TTM 2.12b) / Revenue TTM)
Gross Margin QoQ = 62.25% (prev 62.18%)
Tobins Q-Ratio = 3.04 (Enterprise Value 26.7b / Total Assets 8.78b)
Interest Expense / Debt = 3.40% (Interest Expense 34.8m / Debt 1.02b)
Taxrate = 20.16% (383.7m / 1.90b)
NOPAT = 1.54b (EBIT 1.93b * (1 - 20.16%))
Current Ratio = 3.01 (Total Current Assets 4.06b / Total Current Liabilities 1.35b)
Debt / Equity = 0.16 (Debt 1.02b / totalStockholderEquity, last quarter 6.49b)
Debt / EBITDA = -0.29 (Net Debt -638.3m / EBITDA 2.19b)
Debt / FCF = -0.37 (Net Debt -638.3m / FCF TTM 1.75b)
Total Stockholder Equity = 6.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.59% (Net Income 1.52b / Total Assets 8.78b)
RoE = 24.41% (Net Income TTM 1.52b / Total Stockholder Equity 6.23b)
RoCE = 29.15% (EBIT 1.93b / Capital Employed (Equity 6.23b + L.T.Debt 404.2m))
RoIC = 20.72% (NOPAT 1.54b / Invested Capital 7.45b)
WACC = 7.50% (E(27.4b)/V(28.4b) * Re(7.68%) + D(1.02b)/V(28.4b) * Rd(3.40%) * (1-Tc(0.20)))
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.04 | Cagr: -0.15%
[DCF] Terminal Value 76.86% ; FCFF base≈1.67b ; Y1≈1.84b ; Y5≈2.35b
[DCF] Fair Price = 251.9 (EV 35.9b - Net Debt -638.3m = Equity 36.5b / Shares 145.1m; r=8.35% [WACC [floored]]; 5y FCF grow 11.75% → 2.50% )
EPS Correlation: 99.43 | EPS CAGR: 21.19% | SUE: 0.62 | # QB: 0
Revenue Correlation: 99.89 | Revenue CAGR: 9.93% | SUE: 0.64 | # QB: 0
EPS next Quarter (2026-09-30): EPS=2.85 | Chg30d=-0.38% | Revisions=-9% | Analysts=4
EPS current Year (2026-06-30): EPS=11.11 | Chg30d=+0.37% | Revisions=+57% | GrowthEPS=+16.3% | GrowthRev=+9.8%
EPS next Year (2027-06-30): EPS=12.10 | Chg30d=-0.54% | Revisions=+13% | GrowthEPS=+8.9% | GrowthRev=+7.9%
[Analyst] Revisions Ratio: +57%